Introduction {#s1}
============

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer deaths in the world ([@B7]). Alcoholic liver disease is the most common cause of HCC, accounting for about one-third of all HCC cases ([@B18]). However, alcohol abuse may not be the only risk factor for HCC. Because even cessation of alcohol consumption, alcoholic liver disease patients still could develop HCC within 1--10 years ([@B3]). This suggests that alcohol consumption could synergistic with other risk factors for HCC development. Emerging studies have confirmed that epigenetic changes are critical events in the development and progression of liver cancer ([@B20]). Epigenetic mechanisms including hypomethylation induced activation of silent oncogenes, loss of imprint, and genomic instability of repetitive DNA sequence. A previous study observed abnormal hypermethylation of specific genes (RASSF1A, GSTP1, CHRNA3, and DOK1) in HCC tumors compared to the cirrhotic liver or normal liver tissue ([@B15]). Also, many studies have found that DNA hypomethylation is associated with the development of HCC. Gao et al. reported that hypomethylation of promoter region of LINE-1 gene, especially at the CpG sites 7 and 18, was significantly associated with poor prognosis of liver cancer ([@B8]). In addition, the interaction between global hypomethylation and regional hypermethylation of genes promotes the progression of liver cancer. For example, DNA hypermethylation induced inactivation of E-cadherin and hypomethylation up-regulated the expression of vimentin, which interact with each other to promote the occurrence and development of liver cancer with poor prognosis ([@B14]).

Tumor necrosis factor alpha (TNFα) is considered to be a critical pro-inflammatory molecule in alcoholic liver injury ([@B5]). Tumor necrosis factor (TNF) receptor superfamily member 12A (TNFRSF12A; also known as CD266, and TWEAKR) was reported to be upregulated in alcoholic hepatitis ([@B1]). There are increasing evidence prove that the expression of TNFRSF12A is elevated in various cancers, including breast cancer ([@B25]), glioma ([@B22]), esophageal adenocarcinoma ([@B24]), pancreatic cancer ([@B10]), and HCC ([@B16]; [@B23]). Moreover, the over expression of TNFRSF12A is associated with poor prognosis in all these tumors. TNFRSF12A is expressed in progenitor cells in response to liver injury ([@B12]; [@B21]). In a mouse model of liver injury maintained on a choline-deficient diet, Bibikova et al. demonstrated that TNFRSF12A promoted the proliferation of liver progenitors ([@B2]). Ethanol administration to these mice resulted in increased expression of TNFRSF12A in the liver, ([@B21]). TNFRSF12A is mainly expressed in a subset of hepatocytes and progenitor cells of patients with alcoholic hepatitis. Colocalization of TNFRSF12A with progenitor-derived neonatal hepatocytes in the liver from alcoholic hepatitis patients suggests a potential role for this receptor in progenitor cell differentiation.

In this study, we mined the publicly available database TCGA and GEO aim to: (1) identify the methylation sites in TNFRSF12A which associated with the development of HCC patients with history of alcohol abuse. (2) analyzed the probable regulatory mechanism of TNFRSF12A methylation by methyltransferases in prognosis of HCC with alcoholic hepatitis.

Materials And Methods {#s2}
=====================

Data Collection From TCGA And GEO Database {#s2_1}
------------------------------------------

The preprocessed level 3 whole genome methylation microarray data and corresponding clinical data for HCC cases were obtained through the Cancer Genome Atlas (TCGA; <https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>). At the same time, the mRNA data was extracted from RNA sequencing data on HCC in TCGA. At first, we extracted 371 HCC patient's data which including 371 cancer samples and 50 paracancerous normal samples from TCGA. After data linking, 345 HCC cases which have completely clinical prognostic information, history of risk factors, mRNA data and methylation data were included in final analysis. The whole genome methylation data of 132 liver disease patients and 34 normal tissues were extracted from the GSE60753 dataset of GPL13534 platform in Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih.gov/geo>). In this study, the criteria to identify the alcohol abuse were as same as the criteria identified in the GSE60753 dataset ([@B11]). DNA methyltransferases (DNMT1, DNMT2, DNMT3A, DNMT3B, DNMT3L) and TNFRSF12A gene mRNA data were extracted from DNA microarray in 15 patients with alcoholic hepatitis from the GSE28619 dataset of GPL570 platform in GEO.

Methylation and Gene Expression Analysis {#s2_2}
----------------------------------------

Gene expression was defined using the raw read count and log2 transformed normalized count. Whole genome methylation data were measured by Illumina Human methylated 450k microarrays for HCC in TCGA dataset. In GSE60753 dataset, the methylation level was measured by Illumina Human methylated 27k microarrays. The methylation level of CpG islands were represented as β values. B = Intensity of the methylated allele (M)/\[Intensity of the unmethylated allele (U) + Intensity of the methylated allele (M) + 100\] ([@B80]). The β values will map to genome (methylation site/gene) and used to perform DNA methylation analysis. Any methylation site corresponding to the TNFRSF12A gene without a β value was excluded. The final identified sites list included 19 methylation sites identified from the TCGA database, and 12 methylation sites identified from the GSE60753 dataset ([**Table 1**](#T1){ref-type="table"}). We used the median value of the methylation level as the cutoff point to divide the patients into hypomethylation and hypermethylation groups. Similarly, the median value of TNFRSF12A expression was used as the cutoff point to divide patients into high expression group and low expression group.

###### 

Methylation sites corresponding to TNFRSF12A in TCGA database and GSE60753 dataset.

  **Methylation: sites**   **Is there a β value? (yes or no)**   **Start**   **End**   **Gene symbol**   **Feature type**   
  ------------------------ ------------------------------------- ----------- --------- ----------------- ------------------ ---------
  **cg00510447**           Yes                                   Yes         3021607   3021608           TNFRSF12A          S_Shore
  **cg26808293**           Yes                                   Yes         3022206   3022207           TNFRSF12A          S_Shore
  **cg06209210**           Yes                                   Yes         3020915   3020916           CLDN6;TNFRSF12A    Island
  **cg15460516**           Yes                                   Yes         3020248   3020249           CLDN6;TNFRSF12A    Island
  **cg05336707**           Yes                                   Yes         3020469   3020470           CLDN6;TNFRSF12A    Island
  **cg20195987**           Yes                                   Yes         3021145   3021146           CLDN6;TNFRSF12A    Island
  **cg08798492**           Yes                                   Yes         3020268   3020269           CLDN6;TNFRSF12A    Island
  **cg06097320**           Yes                                   Yes         3020244   3020245           CLDN6;TNFRSF12A    Island
  **cg02105042**           Yes                                   Yes         3019455   3019456           CLDN6;TNFRSF12A    N_Shore
  **cg02199397**           Yes                                   No          3018314   3018315           CLDN6;TNFRSF12A    Island
  **cg08934846**           Yes                                   No          3018344   3018345           CLDN6;TNFRSF12A    Island
  **cg07384961**           Yes                                   No          3018127   3018128           CLDN6;TNFRSF12A    Island
  **cg10293804**           Yes                                   No          3018528   3018529           CLDN6;TNFRSF12A    S_Shore
  **cg08563839**           Yes                                   No          3017499   3017500           CLDN6;TNFRSF12A    N_Shore
  **cg06036912**           Yes                                   No          3018339   3018340           CLDN6;TNFRSF12A    Island
  **cg17865114**           Yes                                   No          3017758   3017759           CLDN6;TNFRSF12A    Island
  **cg06080729**           Yes                                   No          3017625   3017626           CLDN6;TNFRSF12A    Island
  **cg08935125**           Yes                                   No          3018084   3018085           CLDN6;TNFRSF12A    Island
  **cg02732252**           Yes                                   No          3018013   3018014           CLDN6;TNFRSF12A    Island
  **cg00572487**           No                                    Yes         3020062   3020063           CLDN6;TNFRSF12A    N_Shore
  **cg06712763**           No                                    Yes         3020056   3020057           CLDN6;TNFRSF12A    N_Shore
  **cg16657615**           No                                    Yes         3020629   3020630           CLDN6;TNFRSF12A    Island
  **cg06473109**           No                                    No          3018466   3018467           CLDN6;TNFRSF12A    S_Shore
  **cg10298701**           No                                    No          3018474   3018475           CLDN6;TNFRSF12A    S_Shore
  **cg14618624**           No                                    No          3018381   3018382           CLDN6;TNFRSF12A    S_Shore
  **cg20035459**           No                                    No          3018706   3018707           CLDN6;TNFRSF12A    S_Shore

Statistical Analysis {#s2_3}
--------------------

The continuous variables were expressed as mean ± standard deviation or median (quartile range), and categorical variables were presented as frequencies (percentages). Wilcoxon rank sum test was used to compare the differences of methylation level between normal and HCC tissues, or between normal and liver disease tissues (*p*-value \<1.0E−7 were considered as statistically significant). Independent samples t-test was used to analyze the expression differences of TNFRSF12A gene between HCC patients with alcohol abuse risk factor and non-alcoholic risk factor. Kruskal--Wallis H test was used to compare multiple sets of independent samples. Cox proportional hazard regression model was conducted to analyze the effect of methylation level of each site of TNFRSF12A identified in the TCGA database on the overall survival rate of HCC patients when adjusted for covariables. Kaplan--Meier survival curve analysis and log-rank method were used to compare the survival time of different levels of study factors. A linear correlation model was performed to evaluate the relationships between the variables and using Pearson correlation coefficient or Spearman rank correlation coefficient to present the result. Unless otherwise indicated, all statistical tests were two-sided and *p*-value \< 0.05 were considered as statistically significant. All analyses were performed using R (V 3.4.2) software. Normalization pretreatment of methylation data was done using the R *limma* package; Kaplan--Meier survival analysis and Cox proportional hazard regression analysis were performed by R *survival* package. The interaction analysis among the methylation sites, clinicopathological features, and the survival status were conduct by R *HH* package ancova function. Linear correlation analysis between variables was conducted by R *Hmisc* package and the visualization of the correlation coefficient between DNA methylase level, TNFRSF12A gene expression level and TNFRSF12A gene methylation site were performed by R *PerformanceAnalytics* package chart.correlation function.

Results {#s3}
=======

Clinicopathological Characteristics of Patients In TCGA And GEO Database {#s3_1}
------------------------------------------------------------------------

Among the 345 HCC patients from TCGA, 67.8% was male, and 32.2% was female, with an average age of 59.34 ± 13.13 years; 144 (41.7%) were Asians, 192 (55.7%) were non-Asian, and nine of unknown race. These HCC patients included 116 cases that had a history of alcohol abuse, 140 cases that had other non-alcoholic risk factors, and 89 cases that had no major risk factors. The median survival time of these patients was 18.92 months. The main demographic and clinicopathological characteristics of HCC patients from TCGA were presented in [**Table 2**](#T2){ref-type="table"}. Among the woabuse as risk factor (HCC-EtOH); three were cryptogenic cirrhosis; two were biliary cirrhosis; four were genetic cirrhosis; 2 were immune cirrhosis; 21 cases were cirrhosis with chronic alcohol abuse(cirr-EtOH); six cases were cirrhosis with infection of HBV(cirr-HBV); 39 cases were cirrhosis with infection of hepatitis C virus(cirr-HCV); five cases of cryptogenic HCC; 12 cases were HCC with HCV(HCC-HCV); 21 cases of unclassified liver and two cases of biliary tumor. There was no demographic information of patients in GSE60753 dataset.

###### 

Clinicopathological characteristics of the HCC patients in TCGA database.

  Clinicopathological variables                TCGA (n = 345)   Percentage (%)
  -------------------------------------------- ---------------- ----------------
  **Gender**                                                    
   Male                                        234              67.80
   Female                                      111              32.20
  **Race**                                                      
   Asians                                      144              41.70
   Other                                       192              55.70
   Unknown                                     9                2.60
  **Residual tumor status**                                     
   With tumor                                  140              40.60
   Tumor-free                                  190              55.10
   Unknown                                     15               4.40
  **Recurrence**                                                
   YES                                         161              46.70
   NO                                          184              53.30
  **BMI**                                                       
   \< 25                                       186              53.90
   ≥25                                         159              46.10
  **HBV**                                                       
   Positive                                    102              29.56
   Negative                                    232              67.25
   Unknow                                      11               3.19
  **HCV**                                                       
   Positive                                    52               15.07
   Negative                                    282              81.74
   Unknow                                      11               3.19
  **Risk factor history**                                       
   Alcohol abuse^\*^                           116              33.60
   Other risk factor without alcoholic abuse   140              40.60
   No history of primary risk factors          89               25.80
  **Histologic Grade**                                          
   Grade 1--Grade 2                            217              62.90
   Grade 3--Grade 4                            125              26.20
   Unknown                                     3                0.90
  **TNM stage^¶^**                                              
   Stage 1                                     174              50.40
   Stage 2                                     80               23.20
   Stage 3                                     91               26.40

^\*^Among the 116 patients with alcohol abuse history, 24 patients were HBV positive and 19 patients were HCV positive. **^¶^**Stage 1 includes stage I; Stage 2 includes stage II; stage 3 includes stages IIIA, IIIB, IIIC, IV (IVA, IVB).

Methylation Status in the TNFRSF12A Gene {#s3_2}
----------------------------------------

Overall, out of the 19 methylation sites corresponding to TNFRSF12A identified in the TCGA, significant differences were seen in five methylation sites between HCC cancerous and paracancerous tissues (*p* \<1.0E−7, \|logFC\| \>0.8). Among these five sites, cg00510447 and cg26808293 had a logFC\<−0.8; cg06036912, cg08934846, and cg02199397 had a logFC \>0.8 ([**Figure 1A**](#f1){ref-type="fig"}). Out of the 12 sites identified in the GSE60753 dataset, only methylation of cg00510447 and cg26808293 were significantly different between normal and liver diseases tissues ([**Figure 1B**](#f1){ref-type="fig"}). Moreover, the methylation level of cg00510447 and cg26808293 are the highest in the 19 methylation sites identified in TCGA between HCC and cancer adjacent tissues ([**Figure 1C**](#f1){ref-type="fig"}). Linear correlation analysis demonstrated a statistically significant correlation between three methylation sites (cg00510447, cg26808293, cg02105042) and the expression of TNFRSF12A. Among them, the methylation levels of cg00510447 and cg26808293 have strongest negative correlation with the expression level of TNFRSF12A gene (*r* = −0.381 and *r* = −0.373, respectively). ([**Table 3**](#T3){ref-type="table"}, [**Figure 2**](#f2){ref-type="fig"}).

![Significant differences in methylation levels at each site of TNFRSF12A gene in liver diseases. **(A)** A volcano plot depicting methylated level of each sites of TNFRSF12A between HCC tumor and non-tumor tissues from TCGA. X-axis is represented as log10 fold change and Y-axis as −log10 of *p*-value. Methylation with logFC \> 0.8 and *p \<*1.0E−7(marked as red plots) or logFC \<−0.8 and *p \<* 1.0E−7(marked as green plots) were considered differentially significant. **(B)** A Manhattan plot showing the methylation level of 12 sites identified in the GSE60753 dataset. Methylation of cg00510447 and cg26808293 in TNFRSF12A was significantly different between normal and liver disease tissues. (blue line: *p* = 1.0E−5; red line: *p* = 1.0E−7) **(C)** Manhattan plot showing methylation level of the 19 sites in TNFRSF12A from the TCGA (blue line: *p* = 1.0E−5; red line: *p* = 1.0E−7).](fgene-10-01299-g001){#f1}

###### 

The correlation analysis between methylation levels of methylation sites and expression level of TNFRSF12A.

  Methylation sites   Correlation coefficient(*r*)   *p* value
  ------------------- ------------------------------ -----------
  **cg00510447**      −0.381                         3.642E−14
  **cg26808293**      −0.373                         1.407E−13
  **cg02105042**      −0.142                         0.0064
  **cg08563839**      0.086                          0.0998
  **cg06209210**      −0.017                         0.7437
  **cg15460516**      −0.001                         0.9821
  **cg20195987**      −0.063                         0.2306
  **cg08935125**      −0.050                         0.3386
  **cg05336707**      0.041                          0.4313
  **cg02199397**      −0.041                         0.4276
  **cg06080729**      0.083                          0.1132
  **cg08934846**      0.016                          0.7525
  **cg07384961**      −0.008                         0.8710
  **cg06097320**      −0.052                         0.3231
  **cg08798492**      0.041                          0.4352
  **cg10293804**      −0.003                         0.9507
  **cg17865114**      0.056                          0.2803
  **cg02732252**      −0.023                         0.6669
  **cg06036912**      −0.049                         0.3486

![Scatterplot showing the correlation between methylation levels of cg00510447 and cg26808293 and TNFRSF12A expression in HCC cases. **(A)** The correlation between cg00510447 methylation level and TNFRSF12A expression level. **(B)** The correlation between cg26808293 methylation level and TNFRSF12A expression level.](fgene-10-01299-g002){#f2}

Predictive Value Of Methylation Sites in the TNFRSF12A Gene for HCC Prognosis {#s3_3}
-----------------------------------------------------------------------------

The Cox proportional hazards regression model was used to analyze the relationship between the methylation level of TNFRSF12A and survival of HCC patients which adjusting for age, gender, race, histological grade, residual tumor status(presence or absence), BMI, recurrence status, history of HCC risk factors, and TNM staging. [**Table 4**](#T4){ref-type="table"} shows the prognostic analysis results of the 19 methylation sites ranked by the *p*-values. The prognostic analysis results showed that hypermethylation of cg00510447 (HR = 0.03, *p* = 0.04) and cg26808293(HR = 0.02, *p* = 0.02) may offer a favorable prognosis of HCC. Hypermethylation of cg15460516 (HR = 3.93E13, *p* = 0.001) and cg06209210 (HR = 8.49E6, *p* = 0.012) was identified as a risk factor affecting the prognosis of HCC.

###### 

Cox proportional hazard regression analysis of the relationship between the methylation sites of TNFRSF12A and survival rate of HCC patients from TCGA.

  Methylation sites   HR (95%CI)^¶^                 *p* value
  ------------------- ----------------------------- -----------
  **cg15460516**      3.93E+13(7.47E+5--2.07E+21)   0.001
  **cg26808293**      0.02(0--0.24)                 0.002
  **cg00510447**      0.03(0--0.31)                 0.004
  **cg06209210**      8.49E+6(34.83--2.07E+12)      0.012
  **cg06080729**      9.28(0.63--136.21)            0.104
  **cg05336707**      1.44E+17(0--1.10E+43)         0.194
  **cg08935125**      0.41(0.09--1.77)              0.231
  **cg08934846**      1.58(0.74--3.37)              0.235
  **cg20195987**      0(0--1715421.33)              0.265
  **cg02199397**      1.67(0.58--4.80)              0.339
  **cg08798492**      10.34(0.05--2009.14)          0.385
  **cg07384961**      0.67(0.26--1.76)              0.419
  **cg10293804**      1.30(0.60--2.83)              0.510
  **cg06097320**      0(0--16665008.15)             0.592
  **cg17865114**      1.80(0.14--23.41)             0.653
  **cg02732252**      1.25(0.41--3.82)              0.699
  **cg02105042**      0.89(0.26--3.05)              0.853
  **cg08563839**      1.23(0.10--14.47)             0.868
  **cg06036912**      1.05(0.40--2.79)              0.916

^¶^The model adjusted for age, gender, race, histological grade, residual tumor status, BMI, recurrence status, history of HCC risk factors, and TNM stage.

Stratified Survival Analysis of cg00510447 and cg26808293 in HCC Patients With and Without Alcohol Abuse {#s3_4}
--------------------------------------------------------------------------------------------------------

Kruskal--Wallis analysis of the methylation level in 132 liver disease cases from GSE60753 dataset showed that cg00510447 and cg26808293 were hypomethylated in HCC cases compared to other liver diseases (*p* = 0.017 and *p* = 0.010, respectively). Further analysis showed that in those non-HCC liver disease cases, the methylation level of these two sites was lower in alcoholic cirrhosis than other liver diseases ([**Figure 3A**](#f3){ref-type="fig"}). Then, the stratified survival analysis show that in 140 HCC cases from TCGA which without alcoholic abuse risk factor, there was no significant difference of prognostic value between different level of TNFRSF12A expression and different methylation level of cg00510447 and cg26808293 ([**Figure 3B**](#f3){ref-type="fig"}). However, in 116 HCC cases which have the alcohol abuse risk factor, there was a significant prognostic association of TNFRSF12A high expression, hypomethylated cg00510447 and hypomethylated cg26808293 ([**Figure 3C**](#f3){ref-type="fig"}). Furthermore, hypomethylation of cg00510447 combined with hypomethylation of cg26808293 predicted worse prognosis in HCC patients with alcohol abuse risk factor ([**Figure 3D**](#f3){ref-type="fig"}).

![Methylation levels of cg00510447 and cg26808293 in liver disease and prognostic association in HCC patients with or without alcoholic risk factors. **(A)** Beeswarm plot showing significant difference in the methylation levels of the two methylation sites in 132 cases of multiple liver disease cases (15 cases of HCCEtoh; 21 cases of cirrEtoh; six cases of cirrHBV; 39 cases of cirrHCV; five cases of Cryptogenic HCC; 12 cases of HCC HCV; 11 cases of other cirrhosis; 23 cases of other liver disease), cg00510447 and cg26808293, which significantly indicated p value \< 0.05. **(B)** Kaplan--Meier survival curves of high and low expression of TNFRSF12A and hypermethylation and hypomethylation of cg00510447 and cg26808293 in 140 HCC cases with non-alcoholic risk factors. **(C)** Kaplan--Meier survival curves of high and low expression of TNFRSF12A and hypermethylation and hypomethylation of cg00510447 and cg26808293 in 116 cases of HCC with a risk alcohol consumption. **(D)** Kaplan--Meier survival curve of the association between hypomethylation of cg26808293 combined with hypomethylation of cg00510447 and hypermethylation of cg26808293 combined with hypermethylation of cg00510447in hepatocellular carcinoma cases with risk factors of alcohol consumption.](fgene-10-01299-g003){#f3}

Interaction Between Methylation Sites and Clinicopathological Characteristics {#s3_5}
-----------------------------------------------------------------------------

We conducted interaction analysis using methylation levels of cg00510447 and cg26808293 as continuous variables, the clinicopathological characteristics including age, gender, race, histological grade, presence or absence of residual tumors, BMI, recurrence, hepatocellular carcinoma risk factor history, TNM stage as attribute covariables, and overall survival status of HCC as the response variable. Results showed that only the interaction between methylation level of cg26808293 and gender was statistically significant (*p* = 0.036) ([**Table 5**](#T5){ref-type="table"}, [**Figure 4A**](#f4){ref-type="fig"}). Therefore, we conducted further stratified survival analysis by different gender. Results showed that the prognostic predictive value of cg26808293 in males was better than females. Kaplan--Meier survival curve showed that the prognosis of hypomethylation in cg26808293 worse than hypermethylation for male HCC patients (*p* = 0.004) ([**Figures 4B**, **C**](#f4){ref-type="fig"}). Moreover, the stratified analysis for male HCC patients with or without history of alcohol abuse showed that the prognosis of hypomethylated cg26808293 was significantly lower in male HCC patients with a history of alcohol abuse (*p* = 0.002). However, these differences have not observed in those male HCC patients with non-alcoholic risk factors ([**Figures 4D, E**](#f4){ref-type="fig"}).

###### 

Interaction of two methylation sites (cg00510447 and cg26808293) with clinicopathological characteristics.

  Response: survival status                                                                                       
  --------------------------- -------- -------------------------------- ---------- ------------------------------ ----------
  **cg00510447**              0.0225   **cg00510447**                   0.0241     **cg00510447**                 0.0223
  **race**                    0.0151   **BMI**                          0.8462     **risk factors**               0.0058
  **cg00510447\*race**        0.2970   **cg00510447\*BMI**              0.3733     **cg00510447\*risk factors**   0.4668
  **cg26808293**              0.0091   **cg26808293**                   0.0096     **cg26808293**                 0.0090
  **race**                    0.0183   **BMI**                          0.8974     **risk factors**               0.0065
  **cg26808293\*race**        0.5410   **cg26808293\*BMI**              0.0995     **cg26808293\*risk factors**   0.9900
  **cg00510447**              0.0235   **cg00510447**                   0.0202     **cg00510447**                 0.0192
  **age**                     0.4150   **recurrence**                   \<0.0001   **stage**                      \<0.0001
  **cg00510447\*age**         0.0667   **cg00510447\*recurrence**       0.1576     **cg00510447\*stage**          0.0707
  **cg26808293**              0.0097   **cg26808293**                   0.0079     **cg26808293**                 0.0076
  **age**                     0.4461   **recurrence**                   \<0.0001   **stage**                      \<0.0001
  **cg26808293\*age**         0.2320   **cg26808293\*recurrence**       0.7810     **cg26808293\*stage**          0.7015
  **cg00510447**              0.0230   **cg00510447**                   0.0167     **cg00510447**                 0.0236
  **gender**                  0.0416   **residual tumor**               \<0.0001   **grade**                      0.0704
  **cg00510447\*gender**      0.1142   **cg00510447\*residual tumor**   0.6943     **cg00510447\*race**           0.9983
  **cg26808293**              0.0091   **cg26808293**                   0.0058     **cg26808293**                 0.0093
  **gender**                  0.0649   **residual tumor**               \<0.0001   **grade**                      0.0652
  **cg26808293\*gender**      0.0363   **cg26808293\*residual tumor**   0.1111     **cg26808293\*grade**          0.4151

![Interactions between methylation site cg26808293 and clinicopathological variables. **(A)** The methylation level of cg26808293 interacts with the gender variable in the survival state. The methylation level of cg26808293 was used as a continuous variable, the gender of HCC was used as an attribute variable, and the patient's prognosis was the response variable. **(B)** The Kaplan--Meier survival curve of hypermethylation and hypomethylation of cg26808293 in male HCC cases. **(C)** The Kaplan--Meier survival curve of hypermethylation and hypomethylation of cg26808293 in female HCC cases. **(D)** The Kaplan--Meier survival curve of hypermethylation and hypomethylation of cg26808293 in male HCC cases with alcohol abuse history. **(E)** The Kaplan--Meier survival curve of hypermethylation and hypomethylation of cg26808293 in male HCC cases without alcohol abuse history.](fgene-10-01299-g004){#f4}

Correlation Between Methylation Sites in TNFRSF12A and DNA Methylase in HCC {#s3_6}
---------------------------------------------------------------------------

Expression of TNFRSF12A was higher in HCC cases with a history of alcohol abuse (*p* = 0.003) ([**Figure 5A**](#f5){ref-type="fig"}). In the GSE28619 dataset, out of five DNA methylases, only DNMT3Lwas identified to be negatively correlated with TNFRSF12A expression (*r* = −0.66, *p \<* 0.001) in 15 cases of alcoholic hepatitis ([**Figure 5B**](#f5){ref-type="fig"}). Expression of DNMT1, DNMT3B and DNMT3L was identified to be negatively correlated with the expression of TNFRSF12A in 116 HCC with alcohol abuse (*r* \<−0.22, *p \<* 0.01). Moreover, only the expression of DNMT3L was positively correlated with the methylation level of cg00510447 and cg26808293 (*r \>*0.40, *p \<* 0.001) ([**Figure 5C**](#f5){ref-type="fig"}).Compared to alcoholic HCC patients, there was no DNA methylases to be identified have correlation with the expression of TNFRSF12A and DNMT3L expression was not correlated to cg00510447 methylation level in non-alcoholic HCC patients (*p \>* 0.05). Even though there was positive correlation between DNMT3L expression and the methylation level of cg26808293, the correlation trend was weak compare to those in alcoholic HCC patients (*r* = 0.29, *p \<* 0.001) ([**Figure 5D**](#f5){ref-type="fig"}).

![Alcohol and non-alcoholic consumption on DNA methyltransferase expression in liver disease and the correlation between cg00510447 and cg26808293 methylation and TNFRSF12A expression. **(A)** Beeswarm plot showing differences in expression of TNFRSF12A in HCC cases with alcohol abuse history and without alcohol abuse history. **(B)** Correlation coefficient plot shows the association of TNFRSF12A with expression of the five DNA methylases in 15 cases of alcoholic hepatitis. **(C)** Correlation coefficient plot shows the expression level of TNFRSF12A and the methylation level of cg00510447 and cg26808293 and the correlation of expression of five DNA methyltransferases in 116 cases of hepatocellular carcinoma with alcohol consumption. **(D)** Correlation coefficient plot showing the expression level of TNFRSF12A and the methylation level of cg00510447 and cg26808293 and correlation with the five DNA methylases in 140 cases of hepatocellular carcinoma without alcohol abuse.](fgene-10-01299-g005){#f5}

Discussion {#s4}
==========

In the present study, we analyzed the methylation level of TNFRSF12A in HCC and other liver diseases through data mining from publicly available databases. Firstly, we found a higher expression of TNFRSF12A have worse prognosis in HCC patients with a history of alcohol abuse. Further analysis revealed both the cg00510447 and cg26808293 sites in the TNFRSF12A gene were significantly hypomethylated in HCC patients than normal tissues, similarly, these were observed in cases of alcoholic hepatitis. In cases of HCC with a history of alcohol abuse, these two sites hypomethylation predict a worse prognosis than hypermethylation. Furthermore, cg00510447 as well as cg26808293, was negatively correlated with TNFRSF12A expression. Related studies have reported that in the process of tumorigenesis, accompanied by hypermethylation of CpG, the methylation of CpG sites with gene scatter can often occur because of insufficient methylation of the entire genome ([@B4]). Hypomethylation may be associated with abnormal activation of individual genes, which will cause extensive changes in gene expression patterns and is the molecular basis for genomic instability. DNA methylation is the central epigenetic mechanism of human gene expression regulation, and studies have shown that this mechanism change is one of the major molecular variants of malignant tumors ([@B13]; [@B6]).

In this study, we conducted the survival analysis combined the cg00510447 and cg26808293 methylation levels in HCC patients with a history of alcohol abuse. The result shows that combination of these two CpG sites hypomethylation were predictors of poor prognosis in HCC patients with a history of alcohol abuse than hypermethylation of these two sites. These results suggested that hypomethylation of cg00510447 and cg26808293 may activated the expression of TNFRSF12A, resulting in poor prognosis in HCC patients. We also found that hypomethylated cg00510447 and cg26808293 can distinguish alcoholic cirrhosis from other non-HCC liver diseases. Hence, it is safe to imply that the hypomethylation of these two points may provide a new mechanism by which alcoholic hepatitis progresses to HCC. Except for gender, none of the clinicopathological variables showed any interaction between methylation of cg00510447 and survival of patients. In this study, hypomethylation of cg26808293 predicted a poor prognosis only in males with HCC who had a history of alcohol consumption. It is probably because males are likely to consume alcoholic beverages more than women ([@B9]). There is a risk factor for alcohol consumption in long-term natural selection. Hypomethylation of cg26808293 was a predictor of poor prognosis whereas hypermethylation could predict a better prognosis in HCC patients with a history of alcohol consumption. Hypermethylation of cg26808293 could protect males with alcoholic HCC by improving disability-adjusted life year and reducing the burden of disease.

DNA methyltransferases (DNMTs) catalyze the transfer of methyl groups from S-adenosylmethionine to DNA. The mammalian DNMT family has five members-DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L, out of which DNMT1 is the most critical enzyme that regulates methylation of newly synthesized DNA strands under the guidance of a methylated template. Even a transient inhibition of DNMT1 can cause long-term stable demethylation ([@B17]). While targeted cleavage of either DNMT1 or DNMT3b has little effect on DNA methylation and growth in colon cancer HCT116 cells, simultaneous inactivation of both the methyltransferases results in hypomethylation of a wide range of genomes ([@B19]).In this study, we analyzed the correlation between five DNA methyltransferases (DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L) and TNFRSF12A expression data from 15 alcoholic hepatitis patients in the GSE28619 dataset. Only a significant negative correlation was found between DNMT3 and TNFRSF12A expression levels. We further analyzed the relationship among the expression levels of the five DNA methyltransferases, TNFRSF12A expression and methylation levels of cg00510447 and cg26808293 in 116 HCC patients with a history of alcohol consumption. Results showed a significant negative correlation between DNMT1, DNMT3b and DNMT3L and TNFRSF12A expression, and a significant positive relationship with the methylation of cg00510447 and cg26808293. We found that there was no linear correlation between these factors in HCC patients with no history of alcohol consumption. Also, there was a significant but weak linear correlation with the methylation level of cg26808293. Based on the above findings, we speculate that alcohol inhibits DNA methyltransferases, specifically, DNMT1, DNMT3B, DNMT3L, through a metabolic pathway, causing a decrease in 5mC content and alteration in methylation characteristics. In the process of carcinogenesis, alcohol causes expansion of cancerous cell clones. Due to the limitation of maintaining the capacity of DNMT3L during DNA replication, the degree of methylation of the corresponding methylation site is decreased, increasing the expression of TNFRSF12A, thereby affecting the survival prognosis of HCC patients with a history of alcohol consumption. The existence of such epigenetic mechanisms remains to be verified by future studies.

We also performed a Spearman correlation analysis of all mRNA expression levels and TNFRSF12A methylation levels (cg00510447 and cg26808293 two-point averaging levels) in the TCGA-hepatocarcinoma program, the correlation coefficient \|*r*\| \> 0.3 is included in the KEGG pathway. The results of the analysis showed that mRNA associated with TNFRSF12A methylation was mainly enriched into five KEGG pathways, including Carbon metabolism. ([**Supplementary Figure S1**](#SM1){ref-type="supplementary-material"}). Searching for DNMT3L in protein and protein interaction search tools (String) found that eight related proteins are enriched in the protein interaction network and related to KEGG pathway-Alcoholism ([**Supplementary Figure S2**](#SM1){ref-type="supplementary-material"}). In conclusion, whether alcohol affects DNA methylase through one-carbon metabolism pathway and thus reduces the degree of methylation of TNFRSF12A through epigenetic effects, ultimately affecting the prognosis of patients with HCC hepatocellular carcinoma remains to be determined.

Despite a lack of experimental studies to determine the causality of functional and regulatory pathways, our study provided a novel concept that epigenetic mechanisms are involved in the development of HCC, and eventual transformation of alcoholic liver disease into HCC. Our results showed that the methylation status of cg00510447 and cg26808293 corresponding to TNFRSF12A was negatively correlated to the prognosis of HCC with alcoholic cirrhosis. These findings suggested that quantitative detection of methylation at these two points can serve as predictive markers of prognosis in HCC, especially in those with alcohol abuse history. However, mechanisms underlying the hypomethylation of TNFRSF12A in HCC with alcohol abuse history remain unclear. Some studies have shown that this may be related to the dysfunction of methyltransferases. Most significantly, the highly dynamic nature of epigenetic mechanisms offers hope for the discovery of novel therapies in liver disease. Objectively, changing the methylation status of genes through medications or gene therapy can influence the development of liver diseases. DNA methylation can be used as a marker for an early stage of hepatocellular carcinoma. Our study suggested that drugs can be developed to intervene early in the aberrant methylation of TNFRSF12A, transcriptional regulation of the TNFRSF12A gene to improve the survival of patients with HCC with a history of alcohol consumption.
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